ENTITY

Zai Lab (9688 HK)

58
Analysis
Health Care • China
Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative products for oncology, immunology, neuroscience, and infectious diseases. The company has commercialized products such as Zejula, Optune, Qinlock, Nuzyra, and Vyvgart in China. Zai Lab was founded in 2014 and is headquartered in Shanghai, China, and Cambridge, Massachusetts, USA.
more
•02 Oct 2026 09:01

HONG KONG ALPHA PORTFOLIO: (September 2026)

HK Alpha portfolio gained 2.22% in September, outperforming its benchmark by 5.36%. Since inception, the portfolio has outperformed HK indexes by...

Logo
99 Views
Share
•27 Sep 2026 16:52

Technically Speaking Breakouts & Breakdowns - HONG KONG (August 2026)

Genscript shares gain after the company announced it will provide wet-lab services to companies participating in Eli Lilly's TundeLab, helping them...

Logo
118 Views
Share
bullish•Alibaba
•10 Sep 2024 05:49

Alibaba (9988 HK/BABA) Dual Primary Listing: Are We There Yet?

Alibaba will be in included in Southbound Stock Connect from the open of trading today. Volumes should be higher than usual as mainland investors...

Logo
2.6k Views
Share
bullish•Zai Lab
•21 Apr 2026 14:39

Primer: Zai Lab (9688 HK) - Apr 2026

Zai Lab operates on a differentiated 'in-licensing' model, acquiring and commercializing promising drug candidates from global partners for the...

Logo
131 Views
Share
•01 Sep 2026 12:44

HONG KONG ALPHA PORTFOLIO: (August 2026)

HK Alpha portfolio gained 3.45% in August, outperforming its benchmark by 2.67%.  Since inception, the portfolio has outperformed HK indexes by 60%...

Logo
183 Views
Share
x